Boston Scientific is recalling the catheters associated with its POLARx Cryoablation System due to a heightened risk of esophageal injury. The FDA has ruled that this a Class I recall.

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met. 

BAV patients are often excluded from TAVR trials, creating uncertainty about the best way to treat that population when aortic valve replacement is required. To learn more, researchers tracked CMS data from 2018 to 2022, presenting their findings in The Annals of Thoracic Surgery.

An additional 15 patients will now receive BiVacor's titanium total artificial heart technology as they wait for a permanent transplant.

The new device was designed to help patients evaluate their own heart health in real time.

After the significant success of Shockwave Medical's IVL therapy to break up heavily calcified vessels without trauma, there are now several companies working on their own IVL devices. 

The first-in-human procedures were performed in Prague with the investigational Aveir CSP leadless pacemaker system.

Joseph C. Wright, a longtime Merit Medical employee, resigned after unspecified allegations regarding his conduct were brought to light. He was named the company's new president back in May.

Percutaneous treatment was linked to improved survival and fewer adverse events than surgery when patients presented with both symptomatic severe aortic stenosis and complex coronary artery disease. 

Insulet accused multiple parties, including a rival CEO, of working together to copy its insulin pump technology and bring a "clone product" to market.

Screening TAVR patients for signs of depression prior to treatment could help providers adapt as necessary and deliver better patient care.

More than 100 plaintiffs have now sued the Marlborough, Massachusetts-based mammography-maker, claiming they suffered injuries and emotional distress stemming from implantation of the BioZorb radiographic marker. 

“With this signal about the public’s preference for notification, the question for health systems and policymakers is not whether to notify patients but when and how.”